FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Hahn’s FDA Nomination Heads to Full Senate
12/03/2019
 
 
TXT Lawmakers Push for UDIs on Insurance Forms
12/03/2019
 
 
TXT Jobs Lost if Medical Device Tax Not Repealed: Analysis
12/04/2019
 
 
TXT FDA Should Consider Free Speech Decisions: MIWG
12/04/2019
 
 
TXT Groups Question FDA Weight Loss Paper
12/05/2019
 
 
TXT Increased Enforcement on Violative Cell/Tissue Products
12/06/2019
 
 
TXT Judicial Deference to FDA More Uncertain: Analysis
12/03/2019
 
 
TXT Genus Lifesciences Protests FDA Actions on Lannett Application
12/05/2019
 
 
TXT CDRH, CDER Differ on Releasing Gender Info
12/05/2019
 
 
TXT Chara Biologics Markets Unapproved Cell Product: CBER
12/05/2019
 
 
TXT 3rd Circuit Remands Hundreds of Fosamax Cases
12/03/2019
 
 
TXT FDA Launches CURE ID Internet Repository
12/05/2019
 
 
TXT Mullin Reelected ICH Management Committee Chair
12/03/2019
 
 
TXT Latest Federal Register Notices
12/08/2019
 
 
TXT Product Approval Summaries
12/08/2019
 
 
TXT Since Our Last Issue ...
12/08/2019
 
 
TXT Physician Convicted in Insy Therapeutics Scheme
12/06/2019
 
 
TXT Draft Guide on Corticosteroid Products for Hemorrhoids
12/06/2019
 
 
TXT Magnetic Resonance Coil Performance Criteria Guide
12/06/2019
 
 
TXT FDA Seeking NDMA Testing
12/05/2019
 
 
TXT FDA Approves 3 ANDAs for Generic MS Drug
12/05/2019
 
 
TXT Interstitial Cystitis Drug Effectiveness Guidance
12/04/2019
 
 
TXT CDRH Industry Basics Webcast
12/04/2019
 
 
TXT Rising Pharma Paying Over $3 Million in Price Fixing Charge
12/04/2019
 
 
TXT House Drug Price Bill Keeps New Drugs Away: White House
12/04/2019
 
 
TXT Electronic Format Transparency Needed: Comment
12/03/2019
 
 
TXT Latest FDA Warning Letter
12/03/2019
 
 
TXT House Hearing to Grill FDA on Foreign Inspections
12/03/2019
 
 
TXT AnazaoHealth FDA-483
12/03/2019
 
 
TXT QS Violations Found at American Contract Systems
12/03/2019
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving